Literature DB >> 16820376

Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats.

Yoshiko Iwasaki1, Hideyuki Yamato, Tomoko Nii-Kono, Ayako Fujieda, Motoyuki Uchida, Atsuko Hosokawa, Masaru Motojima, Masafumi Fukagawa.   

Abstract

BACKGROUND: Using a rat model of renal failure with normal parathyroid hormone levels, we had demonstrated previously that bone formation decreased depending on the degree of renal dysfunction, and hypothesized that uraemic toxins (UTx) are associated with the development of low-turnover bone development, complicating renal failure. In this study, focusing on indoxyl sulphate (IS) as a representative UTx, we analysed the effect of an oral charcoal adsorbent AST-120, which removes uraemic toxins and their precursors from the gastrointestinal tract, on bone turnover.
METHODS: AST-120 or vehicle was administered orally to model rats with uraemia and low turnover bone. Bone turnover was analysed by histomorphometry. Expression of osteoblast-related genes and oat-3 gene was analysed by reverse transcription polymerase chain reaction.
RESULTS: In rats treated with vehicle, serum IS level increased with time after renal dysfunction, while bone formation decreased accompanied by down-regulation of the parathyroid/parathyroid-related peptide hormone receptor, alkaline phosphatase and osteocalcin genes. Administration of AST-120 inhibited the accumulation of IS in blood and ameliorated bone formation. Bone formation rate was 2.4 +/- 1.7 microm(3)/m(2)/year in controls given vehicle and was 11.7 +/- 2.4 microm(3)/m(2)/year in rats administered with AST-120 (P < 0.05). AST-120 treatment also reversed the down-regulation of osteoblast-related genes. Gene expression of oat-3 was detected in the tibia of rats.
CONCLUSION: Administration of the oral charcoal adsorbent AST-120 decreases the osteoblast cytotoxicity of UTx including IS, and suppresses progression of low bone turnover in uraemic rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820376     DOI: 10.1093/ndt/gfl311

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  19 in total

Review 1.  Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.

Authors:  Ziad Massy; Tilman Drueke
Journal:  J Nephrol       Date:  2017-04-12       Impact factor: 3.902

Review 2.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 3.  Uremic Toxicity and Bone in CKD.

Authors:  Suguru Yamamoto; Masafumi Fukagawa
Journal:  J Nephrol       Date:  2017-06-01       Impact factor: 3.902

Review 4.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Type IIc sodium-dependent phosphate transporter regulates calcium metabolism.

Authors:  Hiroko Segawa; Akemi Onitsuka; Masashi Kuwahata; Etsuyo Hanabusa; Junya Furutani; Ichiro Kaneko; Yuka Tomoe; Fumito Aranami; Natsuki Matsumoto; Mikiko Ito; Mitsuru Matsumoto; Minqi Li; Norio Amizuka; Ken-Ichi Miyamoto
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

6.  Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.

Authors:  K Sumida; Y Ubara; J Hoshino; K Mise; N Hayami; T Suwabe; M Kawada; A Imafuku; R Hiramatsu; E Hasegawa; M Yamanouchi; N Sawa; K Takaichi
Journal:  Osteoporos Int       Date:  2015-11-02       Impact factor: 4.507

7.  Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin.

Authors:  Hiroshi Watanabe; Yoshiaki Sakaguchi; Ryusei Sugimoto; Ken-Ichi Kaneko; Hiroshi Iwata; Shunsuke Kotani; Makoto Nakajima; Yu Ishima; Masaki Otagiri; Toru Maruyama
Journal:  Clin Exp Nephrol       Date:  2013-11-02       Impact factor: 2.801

8.  Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins?

Authors:  Sophie Liabeuf; Griet Glorieux; Aurelie Lenglet; Momar Diouf; Eva Schepers; Lucie Desjardins; Gabriel Choukroun; Raymond Vanholder; Ziad A Massy
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

Review 9.  Optimization of Bone Health in Children before and after Renal Transplantation: Current Perspectives and Future Directions.

Authors:  Kristen Sgambat; Asha Moudgil
Journal:  Front Pediatr       Date:  2014-02-24       Impact factor: 3.418

10.  Indoxyl sulfate promotes apoptosis in cultured osteoblast cells.

Authors:  Young-Hee Kim; Kyung-Ah Kwak; Hyo-Wook Gil; Ho-Yeon Song; Sae-Yong Hong
Journal:  BMC Pharmacol Toxicol       Date:  2013-12-01       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.